We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Phase I Safety and Tolerability Study with EVT 302 Successfully Completed
News

Evotec Phase I Safety and Tolerability Study with EVT 302 Successfully Completed

Evotec Phase I Safety and Tolerability Study with EVT 302 Successfully Completed
News

Evotec Phase I Safety and Tolerability Study with EVT 302 Successfully Completed

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Phase I Safety and Tolerability Study with EVT 302 Successfully Completed"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that it has successfully completed a Phase I safety and tolerability study with EVT 302. The preliminary results confirm the good tolerability profile of EVT 302 and are an encouraging basis for further clinical development.

EVT 302, a reversible and highly selective inhibitor of MAO-B in development for smoking cessation, was investigated in an ascending dose study with repeated daily dosing in a total of 84 healthy young and elderly subjects.

Healthy young male subjects were treated with EVT 302 2.5, 5, 15 mg, or placebo for two weeks, and healthy elderly male and female subjects were treated with EVT 302 2.5 mg, 10 mg, or placebo for four weeks. Each treatment was received by 12 young and/or elderly subjects as appropriate.

The highest dose levels exceed the expected maximum therapeutic dose planned to be used in further clinical trials. For the treatment period and part of the subsequent washout phase the subjects were confined to the clinical research unit.

The study was aimed at investigating safety/tolerability, pharmacokinetics, and pharmacodynamics (inhibition of MAO-B in platelets) during prolonged dosing with EVT 302 as compared to placebo. The study was conducted and successfully completed as planned per protocol. The results are still blinded and will become available as final evaluated data over the next two months.

The preliminary data indicate that EVT 302 was well tolerated in young and elderly subjects up to the highest dose levels tested in this study. Adverse events (AEs) classified as possibly treatment related were transient and mostly of mild intensity; only very few moderate AEs were reported. No severe or serious AEs occurred.

No clinically relevant changes in lab values of haematology or clinical chemistry were noted. In particular, there were no changes in liver function tests, in any subjects.

Advertisement